Van Hollen Applauds Law That Will Encourage New Treatments for Childhood Cancer
Today Maryland Congressman Chris Van Hollen issued the following statement on President Obama’s signing into law the Food and Drug Administration Safety and Innovation Act, which incorporates the Creating Hope Act of 2011 and will encourage the development of new drugs to treat rare pediatric diseases such as childhood cancer:
“As co-chair of the Childhood Cancer Caucus, I have heard too many stories of children and families whose lives have been devastated by childhood cancer. I’m very pleased that the bill being signed by the President today will lead to better, safer treatments for these young people. By incentivizing pharmaceutical companies to invest in developing new drugs for rare pediatric diseases, we are bringing much needed help and hope to thousands of American children and families affected by childhood cancer.”
The Food and Drug Administration Safety and Innovation Act incorporates H.R. 3059, the Creating Hope Act of 2011, legislation introduced by Childhood Cancer Caucus co-chairs Congressman Chris Van Hollen and Congressman Michael McCaul, and Caucus members Congressman G.K. Butterfield and Congresswoman Sue Myrick. The Creating Hope Act expands a program at the Food and Drug Administration (FDA) to award the sponsor of a new, approved drug to treat a rare pediatric disease with a voucher for priority review of another drug application. This voucher can be used by the recipient to accelerate the review of another, perhaps more lucrative, drug or it can be sold to another company.
The legislation builds on the earlier work of the Childhood Cancer Caucus. In 2007, Congressman Van Hollen joined Congresswoman Deborah Pryce in introducing the Caroline Pryce Walker Conquer Childhood Cancer Act, which was signed into law on July 29, 2008.